All In Biotech

NDA 018615 · Pharm Assoc

Sulfatrim

Sulfamethoxazole, Trimethoprim · Oral · Sulfonamide Antimicrobial; Dihydrofolate Reductase Inhibitor Antibacterial

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Jan 7, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

235

70 Phase 3, 31 recruiting

FAERS reports

17,270

15,552 serious, 3,240 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 2, 2026.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 7, 1983 Original approval
2 products under this application
  • SULFATRIM · SULFAMETHOXAZOLE 200MG/5ML; TRIMETHOPRIM 40MG/5ML · SUSPENSION, ORAL · Discontinued
  • SULFATRIM PEDIATRIC · SULFAMETHOXAZOLE 200MG/5ML; TRIMETHOPRIM 40MG/5ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfamethoxazole" as an intervention, any sponsor and status, largest first.

All 235 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,335
  • pyrexia2,299
  • fatigue2,115
  • dyspnoea2,078
  • drug ineffective1,979
  • rash1,951
  • pain1,908
  • arthralgia1,652
  • pruritus1,643
  • infection1,620
  • hypersensitivity1,570
  • joint swelling1,541

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
200560
200636
2007195
2008349
2009556
2010542
2011775
2012541
2013130
2014299
2015621
2016693
2017533
2018889
20191,145
20201,490
20211,904
20221,411
20231,317
20241,696
20251,274
2026774

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,002 on PubMed

Sponsor: Pharm Assoc · Also marketed as Sulfatrim Pediatric

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.